Journal of Clinical Oncology
Articles in this Issue
Prospective study of a novel portable scalp-cooling cap for prevention of chemotherapy-induced alopecia.
e24157 Background: Chemotherapy-induced alopecia (CIA) is one of the most distressing adverse events experienced by patien...
A phase 2 study of telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with advanced solid tumors harboring <i>MET</i> amplification.
TPS3157 Background: MET amplification is a rare alteration occurring at a rate of 0.06%–4.2%, in diffe...
Clinical profile and treatment outcomes of lymphoma patients: A retrospective cohort study.
e19100 Background: Real-world data on lymphoma subtypes from low-income countries remain limited, particularly regarding t...
Effect of breast density reporting on supplemental MRI and ultrasound use.
10568 Background: Mammography has lower sensitivity in women with dense breasts due to masking, as both dense tissue and t...
Liposomal irinotecan combined with oxaliplatin, 5-fluorouracil/leucovorin with or without camrelizumab as preoperative chemotherapy for borderline resectable pancreatic cancer: Preliminary results of a single-center phase II exploratory study.
e16465 Background: Borderline resectable pancreatic cancer (BRPC) lacks established standard preoperative chemotherapy reg...
Early detection of multiple myeloma and MGUS progression risk using artificial intelligence and routine laboratory data.
7519 Background: Multiple myeloma (MM) is a malignant plasma cell disorder that often presents with non-specific symptoms,...
PEG timing in head and neck cancer: Is there a sweet spot? A real world study.
e18116 Background: Malnutrition and dysphagia are common during chemoradiation for head and neck cancer, with 30–50% of pa...
Effects of delayed sodium thiosulfate on cisplatin-induced ototoxicity in pediatric and adolescent patients with cancer: Results from the Japanese Children’s Cancer Group STS-J01 study.
10052 Background: Cisplatin is a cornerstone of therapy for pediatric, adolescent, and adult solid tumors but frequently c...
Pain response with stereotactic body radiation therapy versus conventional external beam radiotherapy for spinal metastases: An updated GRADE-assessed systematic review and meta-analysis of randomized controlled trials.
e15149 Background: Stereotactic body radiation therapy (SBRT) allows for dose-escalated ablative treatment of spinal metas...
Comparative enumeration of circulating tumor cells with PD-L1 overexpression using anti-EpCAM antibody to N-cadherin in solid cancers.
e14530 Background: Minimal cellular residual disease (MCRD) with PD-L1 expression on Circulating tumor cells (CTCs), is hi...
Real-world concordance of tumor mutational burden (TMB) between blood (circulating tumor DNA) and tissue, and its association with immunotherapy response.
2580 Background: Tissue-derived tumor mutation burden (tTMB) ≥10 mutations/Mb is a histology-agnostic predictive biomarker...
CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: Updated results from an open-label, multicenter, phase 1 first-in-human study.
2521 Background: CS2009 is a first-in-class trispecific antibody targeting PD-1, VEGF and CTLA-4. Initial data from this p...
Age-associated genomic instability and inflammatory pathway activation: A pan-cancer multi-omics analysis of the TITANIA framework.
2583 Background: Aging is associated with increased cancer incidence and altered tumor biology, yet molecular mechanisms u...
Real-world analysis of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer.
e12529 Background: Abemaciclib in combination with adjuvant endocrine therapy (ET) improves invasive disease-free survival...
Long-term mortality trends from pancreatic cancer and associated second malignancies in the U.S., 1999 to 2023: A CDC WONDER analysis.
e16369 Background: Pancreatic CA and secondary malignancies are major contributors to U.S. mortality....
Fezolinetant for the management of vasomotor symptoms in patients with breast cancer.
e12521 Background: Approximately 70% of breast cancers are hormone receptor (HR)–positive, for which endocrine therapy (ET...
Independent validation of a model to predict early favorable PSA response (NADIR model) in enzalutamide-treated patients of the ARCHES trial.
5082 Background: Our group recently trained and independently validated a multivariable logistic regression model (NADIR m...
Metabolic signatures of response: 2-hydroxybutyric acid as a biomarker in melanoma patients receiving ipilimumab–nivolumab.
9521 Background: 2-Hydroxybutyric acid (α-HB) is an established biomarker in metabolic disease of insulin resistance and o...
CD103 <sup>⁺</sup> CD8 <sup>⁺</sup> T cells in malignant pleural effusion as a clinically applicable biomarker for immunotherapy response in advanced lung cancer.
e20535 Background: Malignant pleural effusion (MPE) in advanced lung cancer is associated with poor outcomes and limited b...
Clinical feasibility of 68Ga-DOTATATE PET/CT to identify SSTR-positive soft tissue sarcoma for PRRT selection.
TPS11590 Background: Soft tissue sarcomas (STS) are biologically heterogeneous with limited effective systemic options in...
A prospective, single-arm, multicenter, phase IV study to evaluate the efficacy and safety of sonidegib in Chinese patients with locally advanced basal cell carcinoma.
e21555 Background: Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Sonidegib...
Real-world outcomes of FOLFOX with or without bevacizumab in small bowel and ampullary adenocarcinoma: A propensity-matched analysis.
e16488 Background: Small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (ampullary AC) are rare gastrointestinal...
Supportive care prescribing: A real-world comparison of community vs. academic oncology practices.
e23438 Background: The majority of US cancer patients are treated in community settings, which differ from academic center...
Comparative outcomes of squamous and non-squamous penile cancers: Insights from SEER database.
e17031 Background: Penile cancer is a rare neoplasm in Western countries and is typically of squamous cell carcinoma (SCC)...
Insurance and racial disparities in CAR T-cell therapy outcomes: A National Inpatient analysis.
11172 Background: To understand equity gaps for Chimeric antigen receptor T-cell (CAR-T) therapy, we conducted an analysis...